ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Rubric Capital Management LP

Rubric Capital Management LP lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 90.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 56,671 shares of the specialty pharmaceutical company’s stock after selling 547,129 shares during the period. Rubric Capital Management LP’s holdings in ANI Pharmaceuticals were worth $3,381,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp grew its stake in shares of ANI Pharmaceuticals by 1.3% in the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 178 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of ANI Pharmaceuticals by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after purchasing an additional 211 shares during the period. Simplicity Wealth LLC grew its holdings in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 227 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after buying an additional 233 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ ANIP opened at $57.86 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average of $58.36 and a two-hundred day moving average of $60.83. ANI Pharmaceuticals, Inc. has a twelve month low of $48.20 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the prior year, the business earned $1.05 EPS. ANI Pharmaceuticals’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on ANIP shares. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.